NEW YORK, September 22, 2016 /PRNewswire/ --
Transparency Market Research published a report on the global biotechnology market and
claiming that this vibrant market is expected to grow at an average annual growth rate of
CAGR rate of 11.6% by the end of 2017. The data provided indicates that in 2011, the
market was valued at roughly $216.5 billion, yet major changes in the way the industry
operates and innovative developments in the sector, have pushed values to reach $414.5
billion by the end of 2017. Allergan PLC (NYSE: AGN), Tobira Therapeutics, Inc. (NASDAQ:
TBRA), MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), Aerie Pharmaceuticals Inc.
(NASDAQ: AERI), Puma Biotechnology Inc. (NYSE: PBYI).
This week, Allergan PLC (NYSE: AGN) announced the acquisition of biopharmaceutical
company, Tobira Therapeutics, Inc. (NASDAQ: TBRA) in a deal worth as much as $1.7 billion,
a move to gain more exposure in the liver diseases therapies area. Allergan has agreed to
make a direct payment of $28.35 a share in cash and as much as $49.84 a share based on the
successful completion of certain developments, regulatory and commercial milestones. Even
if the company does not reach certain developments, the offer still represents a 498
percent premium to Tobira's closing price of $4.74 a share earlier in the week. Shares of
Tobira skyrocketed over 700 percent after the announcement.
Another small cap company focused on the development of antibody-based products to
address unmet medical needs in the treatment of cancer, MabVax Therapeutics Holdings, Inc.
(NASDAQ: MBVX), has released the current progress of its antibody development program,
HuMab-5B1. MabVax worked on two clinical trials this year with therapeutic agent (MVT-5873)
, a new generation PET imaging product (MVT-2163), and a radio immunotherapy agent
(MVT-1075), and plans on filing an Investigational New Drug with the U.S. Food and Drug
Administration later this year. On August 17th, MabVax Therapeutics reached a corporate
milestone by successfully completing their uplisting and started to trade on NASDAQ
MabVax Therapeutics Holdings, Inc. (MBVX) Phase I trial for MVT-5873 began in the
first quarter of this year to evaluate the safety, tolerability and pharmacokinetics as a
single agent or in combination with a standard of care chemotherapy. The trial is
currently examining patients with metastatic pancreatic cancer. The MVT-2163 is a positron
emission tomography PET imaging agent. The Phase I trial began in the second quarter of
this year. In preclinical models the use of the imaging agent resulted in high-resolution
images of tumors in xenograft animal models, and now being tested on humans in hopes to
help with diagnosis, monitoring, and assessment of patients with pancreatic cancer.
MabVax's collaborations with key cancer research centers and oncology companies include
the Memorial Sloan Kettering Cancer Center, Rockefeller University and Heidelberg Pharma.
Pharmaceutical company, Aerie Pharmaceuticals Inc. (NASDAQ: AERI) continues to rally
after many Wall Street investment research firms upgraded the company to a "buy". Aerie
has disclosed effective phase 3 trial results for its glaucoma drug, Roclatan. Roclatan is
capable of reducing intraocular pressure (IOP) in patients who has glaucoma or ocular
hypertension. Aerie is a clinical-stage pharmaceutical company mainly focused on the
discovery, development and commercialization of first-in-class therapies for the treatment
of patients with diseases of the eye. Ever since the release of the reports, shares soared
over 50 percent and peaked all-time highs at $38.74.
Shares of Puma Biotechnology Inc. (NYSE: PBYI) surged over 13.5 percent after the U.S.
Food and Drug Administration accepted its New Drug Application to treat breast cancer, the
PB272 (Neratinib). Neratinib allows the company to treat extended adjuvant patients with
early stage HER2-overexpressed breast cancer who have also had prior adjuvant breast
cancer therapy with Herceptin (trastuzumab). Puma Biotechnology is a biopharmaceutical
company devoted to the acquisition and development of novel therapeutics for the treatment
For "The Latest Buzz in Financial News", SIGN UP & Visit:
Follow us on Twitter for real time Financial News Updates:
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz
FinancialBuzz.com, a leading financial news informational web portal designed to
provide the latest trends in Market News, Investing News, Personal Finance, Politics,
Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews.
A pioneer in the financially driven digital space, video production and integration of
social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com
also provides financial news PR branding, marketing and advertising for third parties for
disseminating news and original content through our unique media platform that includes
Newswire Delivery, Digital Advertising, Social Media Relations, Video Production,
Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment
advisor or broker-dealer and do not undertake any activities that would require such
registration. The information provided on http://www.FinancialBuzz.com (the "Site") is
either original financial news or paid advertisements provided [exclusively] by our
affiliates (sponsored content), FinancialBuzz.com, a financial news media and pr marketing
firm enters into service agreements with the companies which are the subject to the
articles posted on the Site for advertising such companies. Financialbuzz.com has been
compensated twelve thousand dollars for financial news pr services by a non-affiliated
third party. We are not an independent news media provider and therefore do not represent
or warrant that the information posted on the Site is accurate, unbiased or complete.
FinancialBuzz.com receives fees for producing and presenting the high quality and
sophisticated content on this site along with other financial news pr media services. Our
fees may be either a flat cash sum or negotiated number of securities of the companies
featured on this site, or a combination thereof. The securities are commonly paid in
segments, of which a portion is received upon engagement and the balance is paid on or
near the conclusion of the engagement. FinancialBuzz.com does not undertake to update any
of the information on the Site or continue to post information about any companies the
information contained herein is not intended to be used as the basis for investment
decisions and should not be considered as investment advice or a recommendation. The
information contained herein is not an offer or solicitation to buy, hold or sell any
security. FinancialBuzz.com, members and affiliates are not responsible for any gains or
losses that result from the opinions expressed on the Site, company profiles, quotations
or in other materials or presentations that it publishes electronically or in print.
Investors accept full responsibility for any and all of their investment decisions based
on their own independent research and evaluation of their own investment goals, risk
tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any
amended from time to time. None of the content issued by FinancialBuzz.com constitutes a
recommendation for any investor to purchase, hold or sell any particular security, pursue
a particular investment strategy or that any security is suitable for any investor. This
publication is provided by FinancialBuzz.com. Each investor is solely responsible for
determining whether a particular security or investment strategy is suitable based on
their objectives, other securities holdings, financial situation needs, and tax status.
You agree to consult with your investment advisor, tax and legal consultant before making
any investment decisions. We make no representations as to the completeness, accuracy or
timeless of the material provided. All materials are subject to change without notice.
Information is obtained from sources believed to be reliable, but its accuracy and
Please visit: http://www.financialbuzz.com
For further information:
Media Contact: Danny Abramov, email@example.com, +1-877-601-1879